Literature DB >> 19353248

Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice.

Patricia A Gonnella1, Pedro J Del Nido, Francis X McGowan.   

Abstract

INTRODUCTION: Experimental autoimmune myocarditis (EAM) is mediated by myocardial infiltration by myosin-specific T cells secreting inflammatory cytokines.
MATERIALS AND METHODS: To clarify the role of cytokines in EAM, we compared STAT 6-deficient ((-/-)) with STAT 4(-/-) and wild-type (BALB/CJ) mice following immunization with cardiac myosin peptide (614-629).
RESULTS: Wild-type mice developed severe disease with a small increase in severity in STAT 6(-/-) mice, while STAT 4(-/-) mice were resistant to EAM. STAT 6(-/-) mice had increased splenocyte proliferation and INF-gamma production versus wild type, while STAT 4(-/-) mice had decreased proliferation and INF-gamma. Following oral administration of myosin (614-629), tolerization was induced in wild-type mice evidenced by amelioration of myocarditis and up-regulation of IL-4. Adoptive transfer of splenocytes from orally tolerized mice resulted in inhibition of disease in STAT 6(-/-) mice.
CONCLUSION: These results demonstrate that oral tolerization ameliorates EAM in BALB/CJ mice and indicate a down-regulatory role for STAT 6 genes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353248     DOI: 10.1007/s10875-009-9290-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  55 in total

Review 1.  Transformation of myocarditis and inflammatory cardiomyopathy to idiopathic dilated cardiomyopathy: facts and fiction.

Authors:  Hans R Figulla
Journal:  Med Microbiol Immunol       Date:  2003-11-01       Impact factor: 3.402

2.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

Authors:  D Bryant; L Becker; J Richardson; J Shelton; F Franco; R Peshock; M Thompson; B Giroir
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

3.  The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-gamma and lacking the SOCS-1 gene.

Authors:  D Metcalf; L Di Rago; S Mifsud; L Hartley; W S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway.

Authors:  M Afanasyeva; Y Wang; Z Kaya; E A Stafford; K M Dohmen; A A Sadighi Akha; N R Rose
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

Review 5.  Autoimmunity in myocarditis: relevance of animal models.

Authors:  S A Huber
Journal:  Clin Immunol Immunopathol       Date:  1997-05

6.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

7.  Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease.

Authors:  K Bachmaier; C Pummerer; I Kozieradzki; K Pfeffer; T W Mak; N Neu; J M Penninger
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

Review 8.  Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.

Authors:  Alida L P Caforio; Niall J Mahon; Francesco Tona; William J McKenna
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

9.  IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization.

Authors:  Sang-Jun Ha; Doo-Jin Kim; Kwan-Hyuck Baek; Yung-Dae Yun; Young-Chul Sung
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

10.  Essential role of Stat6 in IL-4 signalling.

Authors:  K Takeda; T Tanaka; W Shi; M Matsumoto; M Minami; S Kashiwamura; K Nakanishi; N Yoshida; T Kishimoto; S Akira
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

View more
  8 in total

Review 1.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

2.  Silencing of STAT4 Protects Against Autoimmune Myocarditis by Regulating Th1/Th2 Immune Response via Inactivation of the NF-κB Pathway in Rats.

Authors:  Yu-Long Xue; Sheng-Xiao Zhang; Chao-Feng Zheng; Yu-Feng Li; Li-Hui Zhang; Yu-Fei Hao; Shu Wang; Xue-Wen Li
Journal:  Inflammation       Date:  2019-08       Impact factor: 4.092

3.  Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.

Authors:  Georgia Fousteri; Amy Dave; Bret Morin; Shaida Omid; Michael Croft; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2011-02-17       Impact factor: 7.094

Review 4.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

5.  Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8.NODAbo transgenic mice.

Authors:  Veena Taneja; Chella S David
Journal:  J Autoimmun       Date:  2009-10-07       Impact factor: 7.094

6.  Peptide immunotherapy for childhood allergy - addressing translational challenges.

Authors:  Karen J Mackenzie; Stephen M Anderton; Jürgen Schwarze
Journal:  Clin Transl Allergy       Date:  2011-11-07       Impact factor: 5.871

Review 7.  Healing the Broken Heart; The Immunomodulatory Effects of Stem Cell Therapy.

Authors:  Marcus J Wagner; Mohsin Khan; Sadia Mohsin
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

Review 8.  Focus on Autoimmune Myocarditis in Graves' Disease: A Case-Based Review.

Authors:  Lujin Wu; Wei Wang; Qianru Leng; Nana Tang; Ning Zhou; Yan Wang; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2021-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.